INDIANAPOLIS / Mar 09, 2023 / Business Wire / Elevance Health (NYSE: ELV) will host an Investor Conference with analysts and investors on March 23, 2023 in New York City. The event will feature presentations and Q&A sessions with the company’s senior leadership team.
The conference will be webcast live beginning at 8:00 a.m. ET and will conclude by 12:00 p.m. ET. All interested parties are invited to register and access the webcast here, or visit the Investor Relations section at ElevanceHealth.com to register. Please visit the Elevance Health website at least 15 minutes early to register and install any necessary audio software.
Presentations from the conference will be available for download on the Investor Relations section of the company’s website. For those unable to listen to the live webcast, a replay will be available on the company’s website at www.elevancehealth.com.
About Elevance Health, Inc.
Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve approximately 119 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.
| Last Trade: | US$333.86 |
| Daily Change: | -4.40 -1.30 |
| Daily Volume: | 336,856 |
| Market Cap: | US$74.200B |
October 21, 2025 August 18, 2025 July 28, 2025 July 17, 2025 April 22, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load